Role of SCC-S2 in Experimental Metastasis and Modulation of VEGFR-2, MMP-1, and MMP-9 Expression

Molecular Therapy

Volumn 13, Issue 5, 2006, Pages 947-955

  Zhang, Chuanbo ^a   Chakravarty, Debyani ^a   Sakabe, Isamu ^a   Mewani, Rajshree R ^a   Boudreau, Howard E ^a   Kumar, Deepak ^a   Ahmad, Imran ^b   Kasid, Usha N ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b NeoPharm Inc   (United States)

Author keywords

breast cancer; cationic liposomes; endothelial cell survival; invasion and metastasis; MMPs; SCC S2; SCC S2 antisense oligo and siRNA; VEGFR 2

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; GELATINASE B; INTERSTITIAL COLLAGENASE; LIPOSOME; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SCC S2; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG FORMULATION; ENDOTHELIUM CELL; FEMALE; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS POTENTIAL; MICROVASCULATURE; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; METALLOPROTEASES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PROTEINS; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

ANIMALIA;

EID: 33645905764     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.11.020     Document Type: Article

References (49)

1. Liotta L.A., Steeg P.S., and Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64 (1991) 327-336
2. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2 (2002) 442-454
3. Chambers A.F., Groom A.C., and MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2 (2002) 563-572
4. Hunter K., Welch D.R., and Liu E.T. Genetic background is an important determinant of metastatic potential. Nat. Genet. 34 (2003) 23-24
5. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3 (2003) 453-458
6. Saharinen P., Tammela T., Karkkainen M.J., and Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 25 (2004) 387-395
7. van 't Veer L.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
8. van de Vijver M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347 (2002) 1999-2009
9. Ramaswamy S., Ross K.N., Lander E.S., and Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33 (2003) 49-54
10. Fidler I.J., and Kripke M.L. Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat. Genet. 34 (2003) 23
11. Patel S., Wang F.H., Whiteside T.L., and Kasid U. Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response. Oral Oncol. 33 (1997) 197-203
12. Kumar D., Whiteside T.L., and Kasid U. Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein. J. Biol. Chem. 275 (2000) 2973-2978
13. You Z., Ouyang H., Lopatin D., Polver P.J., and Wang C.Y. Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. J. Biol. Chem. 276 (2001) 26398-26404
14. Horrevoets A.J., Fontijn R.D., van Zonneveld A.J., de Vries C.J., ten Cate J.W., and Pannekoek H. Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes. Blood 93 (1999) 3418-3431
15. Zhang H.G., et al. Novel tumor necrosis factor alpha-regulated genes in rheumatoid arthritis. Arthritis Rheum. 50 (2004) 420-431
16. Kumar D., Gokhale P., Broustas C., Chakravarty D., Ahmad I., and Kasid U. Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. Oncogene 23 (2004) 612-616
17. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., and Cheresh D.A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4 (1999) 915-924
18. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
19. Mott J.D., and Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16 (2004) 558-564
20. Gokhale P.C., Soldatenkov V., Wang F.H., Rahman A., Dritschilo A., and Kasid U. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer. Gene Ther. 4 (1997) 1289-1299
21. Gokhale P.C., et al. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin. Cancer Res. 8 (2002) 3611-3621
22. Campbell I.D., and Ginsberg M.H. The talin-tail interaction places integrin activation on FERM ground. Trends Biochem. Sci. 29 (2004) 429-435
23. Sieg D.J., et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol. 2 (2000) 249-256
24. Eliceiri B.P., et al. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J. Cell Biol. 157 (2002) 149-160
25. Turner C.E. Paxillin and focal adhesion signalling. Nat. Cell Biol. 2 (2000) E231-E236
26. Playford M.P., and Schaller M.D. The interplay between Src and integrins in normal and tumor biology. Oncogene 23 (2004) 7928-7946
27. Shalaby F., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376 (1995) 62-66
28. Veikkola T., Karkkainen M., Claesson-Welsh L., and Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60 (2000) 203-212
29. Sawasdikosol S., Pratt J.C., Meng W., Eck M.J., and Burakoff S.J. Adapting to multiple personalities: Cbl is also a RING finger ubiquitin ligase. Biochim. Biophys. Acta 1471 (2000) M1-M12
30. Duval M., Bedard-Goulet S., Delisle C., and Gratton J.P. Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination: consequences on nitric oxide production from endothelial cells. J. Biol. Chem. 278 (2003) 20091-20097
31. Elvert G., et al. Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J. Biol. Chem. 278 (2003) 7520-7530
32. Mandriota S.J., Menoud P.A., and Pepper M.S. Transforming growth factor beta 1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells. J. Biol. Chem. 271 (1996) 11500-11505
33. Kleiner D.E., and Stetler-Stevenson W.G. Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol. 43 (1999) S42-S51 (Suppl.)
34. Nelson A.R., Fingleton B., Rothenberg M.L., and Matrisian L.M. Matrix metalloproteinases: biological activity and clinical implications. J. Clin. Oncol. 18 (2000) 1135-1149
35. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17 (2001) 463-516
36. Davidson B., et al. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin. Cancer Res. 10 (2004) 7335-7346
37. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S., and Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120 (2005) 303-313
38. Jiang X., Dutton C.M., Qi W.N., Block J.A., Garamszegi N., and Scully S.P. siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J. Cell. Physiol. 202 (2005) 723-730
39. Poola I., DeWitty R.L., Marshalleck J.J., Bhatnagar R., Abraham J., and Leffall L.D. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat. Med. 11 (2005) 481-483
40. Rolli M., Fransvea E., Pilch J., Saven A., and Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl. Acad. Sci. USA 100 (2003) 9482-9487
41. Bergers G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2 (2000) 737-744
42. Wary K.K., Thakker G.D., Humtsoe J.O., and Yang J. Analysis of VEGF-responsive genes involved in the activation of endothelial cells. Mol. Cancer 2 (2003) 25-37
43. Pufe T., Harde V., Petersen W., Goldring M.B., Tillmann B., and Mentlein R. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. J. Pathol. 202 (2004) 367-374
44. Himelstein B.P., Lee E.J., Sato H., Seiki M., and Muschel R.J. Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line. Oncogene 14 (1997) 1995-1998
45. Belguise K., Kersual N., Galtier F., and Chalbos D. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24 (2005) 1434-1444
46. Jiang Y., and Muschel R.J. Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res. 62 (2002) 1910-1914
47. Liu Z., Brattain M.G., and Appert H. Differential display of reticulocalbin in the highly invasive cell line, MDA-MB-435, versus the poorly invasive cell line, MCF-7. Biochem. Biophys. Res. Commun. 231 (1997) 283-289
48. 2+-activated chloride channel CLCA2. Cancer Res. 59 (1999) 5488-5491
49. Pei J., et al. Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs 15 (2004) 243-253